Literature DB >> 20554731

Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.

Lin Li1, Fabio Turatti, Desiree Crow, James R Bading, Anne-Line Anderson, Erasmus Poku, Paul J Yazaki, Lawrence E Williams, Debra Tamvakis, Paul Sanders, David Leong, Andrew Raubitschek, Peter J Hudson, David Colcher, John E Shively.   

Abstract

UNLABELLED: Diabodies are noncovalent dimers of single-chain antibody fragments that retain the avidity of intact IgG but have more favorable blood clearance than intact IgG. Radiometals offer a wide range of half-lives and emissions for matching imaging and therapy requirements and provide facile labeling of chelate-antibody conjugates. However, because of their high retention and metabolism in the kidney, the use of radiometal-labeled diabodies can be problematic for both imaging and therapy.
METHODS: Having previously shown that (111)In-DOTA-polyethylene glycol (PEG)3400-anti-carcinoembryonic antigen diabody has less than half the kidney uptake and retention of non-PEGylated diabody and that the two have similarly high tumor uptake and retention, we synthesized a similar derivative for an anti-tumor-associated glycoprotein 72 diabody. We also reduced the molecular size of the polydispersed PEG3400 to monodispersed PEG27 and PEG12 (nominal masses of 1,321 and 617, respectively). We performed biodistributions of their DOTA conjugates radiolabeled with (125)I, (111)In, or (64)Cu in tumor-bearing athymic mice.
RESULTS: The addition of PEG3400 to the diabody reduced kidney uptake to a level (approximately 10 percentage injected dose/g) comparable to that obtained with radiometal-labeled intact IgG. The PEG27 and PEG12 diabody conjugates also demonstrated low kidney uptake without reduction of tumor uptake or tumor-to-blood ratios. When radiolabeled with (64)Cu, the DOTA-PEG12 and -PEG27 diabody conjugates gave high-contrast PET images of colon cancer xenografts in athymic mice.
CONCLUSION: PEGylated diabodies may be a valuable platform for delivery of radionuclides and other agents to tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554731      PMCID: PMC3247072          DOI: 10.2967/jnumed.109.074153

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  37 in total

1.  Numerical selection of optimal tumor imaging agents with application to engineered antibodies.

Authors:  L E Williams; A M Wu; P J Yazaki; A Liu; A A Raubitschek; J E Shively; J Y Wong
Journal:  Cancer Biother Radiopharm       Date:  2001-02       Impact factor: 3.099

2.  Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.

Authors:  P J Yazaki; A M Wu; S W Tsai; L E Williams; D N Ikler; J Y Wong; J E Shively; A A Raubitschek
Journal:  Bioconjug Chem       Date:  2001 Mar-Apr       Impact factor: 4.774

3.  Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody.

Authors:  A D Santos; S V Kashmiri; P H Hand; J Schlom; E A Padlan
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

4.  Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.

Authors:  S R Leong; L DeForge; L Presta; T Gonzalez; A Fan; M Reichert; A Chuntharapai; K J Kim; D B Tumas; W P Lee; P Gribling; B Snedecor; H Chen; V Hsei; M Schoenhoff; V Hale; J Deveney; I Koumenis; Z Shahrokh; P McKay; W Galan; B Wagner; D Narindray; C Hébert; G Zapata
Journal:  Cytokine       Date:  2001-11-07       Impact factor: 3.861

5.  Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments.

Authors:  S W Tsai; L Li; L E Williams; A L Anderson; A A Raubitschek; J E Shively
Journal:  Bioconjug Chem       Date:  2001 Mar-Apr       Impact factor: 4.774

6.  Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl- or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions.

Authors:  Lin Li; Shih-Wa Tsai; Anne-Line Anderson; David A Keire; Andrew A Raubitschek; John E Shively
Journal:  Bioconjug Chem       Date:  2002 Jan-Feb       Impact factor: 4.774

7.  High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.

Authors:  M Tempero; P Leichner; J Baranowska-Kortylewicz; K Harrison; S Augustine; J Schlom; J Anderson; J Wisecarver; D Colcher
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

8.  Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications.

Authors:  P J Yazaki; L Shively; C Clark; C W Cheung; W Le; B Szpikowska; J E Shively; A A Raubitschek; A M Wu
Journal:  J Immunol Methods       Date:  2001-07-01       Impact factor: 2.303

9.  99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.

Authors:  A Goel; J Baranowska-Kortylewicz; S H Hinrichs; J Wisecarver; G Pavlinkova; S Augustine; D Colcher; B J Booth; S K Batra
Journal:  J Nucl Med       Date:  2001-10       Impact factor: 10.057

10.  Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.

Authors:  R F Meredith; A J Bueschen; M B Khazaeli; W E Plott; W E Grizzle; R H Wheeler; J Schlom; C D Russell; T Liu; A F LoBuglio
Journal:  J Nucl Med       Date:  1994-06       Impact factor: 10.057

View more
  16 in total

1.  Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice.

Authors:  Haiming Ding; Michelle M Carlton; Stephen P Povoski; Keisha Milum; Krishan Kumar; Shankaran Kothandaraman; George H Hinkle; David Colcher; Rich Brody; Paul D Davis; Alex Pokora; Mitchell Phelps; Edward W Martin; Michael F Tweedle
Journal:  Bioconjug Chem       Date:  2013-10-31       Impact factor: 4.774

2.  Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.

Authors:  Scott M Knowles; Anna M Wu
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

3.  Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model.

Authors:  Patty Wong; Lin Li; Junie Chea; Melissa K Delgado; Erasmus Poku; Barbara Szpikowska; Nicole Bowles; Megan Minnix; David Colcher; Jeffrey Y C Wong; John E Shively; Paul J Yazaki
Journal:  Cancer Biother Radiopharm       Date:  2017-09       Impact factor: 3.099

4.  A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  Dalton Trans       Date:  2011-03-25       Impact factor: 4.390

5.  Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab')2 Fragments of Obinutuzumab in Lymphoma.

Authors:  Lei Kang; Cuicui Li; Zachary T Rosenkrans; Jonathan W Engle; Rongfu Wang; Dawei Jiang; Xiaojie Xu; Weibo Cai
Journal:  J Nucl Med       Date:  2020-08-21       Impact factor: 10.057

6.  Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging.

Authors:  Lin Li; Desiree Crow; Fabio Turatti; James R Bading; Anne-Line Anderson; Erasmus Poku; Paul J Yazaki; Jenny Carmichael; David Leong; David Wheatcroft; Michael P Wheatcroft; Andrew A Raubitschek; Peter J Hudson; David Colcher; John E Shively
Journal:  Bioconjug Chem       Date:  2011-03-24       Impact factor: 4.774

7.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

8.  Single molecular weight discrete PEG compounds: emerging roles in molecular diagnostics, imaging and therapeutics.

Authors:  Stephen P Povoski; Paul D Davis; David Colcher; Edward W Martin
Journal:  Expert Rev Mol Diagn       Date:  2013-05       Impact factor: 5.225

9.  An Efficient Method for Labeling Single Domain Antibody Fragments with 18F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker.

Authors:  Zhengyuan Zhou; Nick Devoogdt; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  Bioconjug Chem       Date:  2018-11-14       Impact factor: 4.774

10.  Generation and characterization of a diabody targeting the αvβ6 integrin.

Authors:  Heide Kogelberg; Enrique Miranda; Jerome Burnet; David Ellison; Berend Tolner; Julie Foster; Carmen Picón; Gareth J Thomas; Tim Meyer; John F Marshall; Stephen J Mather; Kerry Chester
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.